US7550433 — Erythropoietin receptor peptide formulations and uses
Method of Use · Assigned to Affymax Inc · Expires 2026-06-02 · 0y remaining
What this patent protects
This patent protects peptide compounds that act as agonists of the erythropoietin receptor to treat disorders associated with insufficient or defective red blood cell production.
USPTO Abstract
The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1238 |
— | peginesatide-acetate |
U-1238 |
— | peginesatide-acetate |
U-1238 |
— | peginesatide-acetate |
U-1238 |
— | peginesatide-acetate |
U-1238 |
— | peginesatide-acetate |
U-1238 |
— | peginesatide-acetate |
U-1238 |
— | peginesatide-acetate |
U-1238 |
— | peginesatide-acetate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.